Ally Bridge Group (Ny) LLC Viridian Therapeutics, Inc.\De Transaction History

Ally Bridge Group (Ny) LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $4.55 Million - $5.99 Million	201,752 New	201,752 $4.8 Million
Q1 2022 May 16, 2022	SELL	$16.79 - $20.88 $1.83 Million - $2.27 Million	-108,762 Reduced 17.98%	496,012 $9.17 Million
Q4 2021 Feb 14, 2022	SELL	$15.65 - $21.5 $4.7 Million - $6.45 Million	-300,204 Reduced 33.17%	604,774 $12 Million
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $481,776 - $820,237	45,068 Added 5.24%	904,978 $14.9 Million
Q2 2021 Aug 16, 2021	BUY	$14.34 - $18.67 $2.57 Million - $3.34 Million	179,142 Added 26.31%	859,910 $15.7 Million
Q1 2021 May 17, 2021	BUY	$15.5 - $24.93 $10.6 Million - $17 Million	680,768 New	680,768 $11.4 Million

181

76.7M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $795M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.